thisdrug what a medicine's name tells you

WHO naming stem · suffix · 30 listed names

-fibrate

This page was written with AI.

clofibrate derivatives, peroxisome proliferator activated receptor-α (PPAR-α) agonists

WHO's definition, quoted as written in the 2024 stem book

3 of 30 names appear in these lists: 3 in the US list (FDA Drugs@FDA) and 1 in the EU central list (EMA); 3 have national brands in at least one EU/EEA country.

Names only. This page is about -fibrate as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -fibrate. So the letters fibrate sit at the end of the name (…fibrate).

All 30 names WHO lists under -fibrate

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 3 of 30 names appear in these lists: 3 in the US list (FDA Drugs@FDA) and 1 in the EU central list (EMA); 3 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. aluminium clofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  2. bezafibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. biclofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  4. binifibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  5. calcium clofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  6. choline fenofibrate
    US brands: FENOFIBRIC ACID, TRILIPIX (discontinued in FDA listings)
    EU (central) brands: none found
  7. cinnarizine clofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  8. ciprofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. clinofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  10. clofibrate
    US brands: ATROMID-S (discontinued in FDA listings)
    EU (central) brands: none found
  11. dulofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. etofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  13. etofylline clofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  14. fenirofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. fenofibrate
    US brands: ANTARA (MICRONIZED), FENOFIBRIC ACID, LIPOFEN, FENOGLIDE (discontinued in FDA listings), LIPIDIL (discontinued in FDA listings), TRICOR (discontinued in FDA listings), TRICOR (MICRONIZED) (discontinued in FDA listings), TRIGLIDE (discontinued in FDA listings), TRILIPIX (discontinued in FDA listings)
    EU (central) brands, in combination: Cholib with simvastatin; Pravafenix with pravastatin
  16. lifibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  17. nicofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  18. pemafibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  19. picafibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  20. ponfibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  21. ronifibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  22. salafibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  23. serfibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  24. simfibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  25. sitofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  26. tiafibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  27. timofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  28. tocofibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  29. urefibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  30. xantifibrate
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Names with these letters that are not clofibrate derivatives, peroxisome proliferator activated receptor-α (PPAR-α) agonists

WHO lists these 2 names under -fibrate, but says the stem is not used in its meaning here: group (b) of Part IV of the 2024 stem book, “INN in which the preferred stem has been used, but not in accordance with its definition”. The letters are marked where they sit; WHO’s note, where it gives one, is quoted as written. In these names, WHO’s definition of -fibrate does not apply.

  1. bromebric acid
  2. fibracillinWHO’s note: antibiotic

Same group, without the stem

WHO also lists these 2 names under -fibrate: group (c) of Part IV of the 2024 stem book, “INN which belong to the same group of pharmaceutical substances but in which the stem is not used”. They belong to the same group of substances as the group (a) names above, yet they do not carry -fibrate, so the name alone does not reveal the group.

  1. nafenopin
  2. treloxinate

Decode another name

Decoded

lifibrate

Listed INNCarries 2 WHO stems, most specific first: -fibrate …

  • -fibrateend of the nameWHO lists it hereWHO definition: clofibrate derivatives, peroxisome proliferator activated receptor-α (PPAR-α) agonists
  • -brateend of the nameWHO lists it hereWHO definition: clofibrate derivatives

“lifibrate” is an INN that WHO lists under -fibrate, -brate in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -fibrate (Part II B) and the 30 names (Part IV, group (a)), and the 2 not in accordance with it (group (b)) and 2 of the same group without the stem (group (c)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy